You may have heard of Colossal Biosciences because they just unveiled three gene-edited wolf pups named Romulus, Remus, and Khaleesi. They’re fluffier, whiter, and bigger than the average gray wolf, bred with spliced-in traits from the extinct Canis dirus — the legendary dire wolf.
But behind the fur and fandom lies something stranger. Colossal isn’t just a de-extinction startup. It’s a synthetic biology juggernaut with nearly half a billion in funding, an elite investor list that includes pop icons and defense-tied billionaires, and a plan to rewrite what it means to be “natural.” These aren’t just wolves. They’re proof-of-concept prototypes. And the company’s real product? Control over life’s building blocks.
This post has been syndicated from Closer to the Edge, where it was published under this address.